ABSTRACT
INTRODUCTION
The first medical use of botulinum neurotoxin (BTX) was described by Dr. Alan Scott during the 1970s, when BTX type A (BTX-A) was used for reducing over-activity of selected periocular muscles in patients with strabismus [1, 2] .
Following this observation, BTXs have been increasingly studied for a wide variety of other therapeutic and aesthetic uses. In the late 1980s, Drs. Jean and Alastair Carruthers observed a reduction of dynamic lines on the forehead of a patient being treated for blepharospasm. They reported their observation in 1992 [3] . Double-blind, placebo-controlled studies using BTX-A for upper facial lines in the USA confirmed their reduction of lower forehead lines for approximately 4 months [4, 5] . These initial observations were followed by double-blind, placebo-controlled studies of several hundred patients in the USA, which demonstrated that BTX-A was safe and effective for reducing the severity of glabellar (lower forehead vertical frown lines) [6, 7] .
A significant improvement was observed a few days after treatment and the mean duration of treatment was in excess of 4 months. This study utilized appropriate doses of onabotulinumtoxinA, with a total of 20 onabotulinumtoxinA units for the lower forehead frown lines. Other studies confirmed that BTX-A is also effective for lateral periorbital lines [8] , infraorbital lines [9] , nasal lines, terional area, the jaw line, and the platysma.
BTXS
There are two main serotypes of BTXs that are used clinically; the most commonly used being BTX-A. BTX type B (BTX-B) has a much shorter duration of effect than BTX-A, but is occasionally used if therapeutic resistance to BTX-A is observed [10] . BTX-A and -B are also effective at reducing sweating in areas such as the axillae [11, 12] . BTX-A treatment for axillary hyperhidrosis has been approved in numerous countries in addition to the USA. A recent study of hyperhidrosis found that the benefit of duration of BTX-B was longer to that seen after intramuscular treatment, but still less than BTX-A [13] . The transport of the BTX-A is by rapid uptake of the light chain of the toxin into the neuromuscular junction, and the presynaptic inhibition of acetylcholine release is thought to be one mode of action of BTX-A (Fig. 1) . As a result, BTX-A results in localized, reversible muscle relaxation (1) . Some facial lines result from repetitive contraction of facial muscles and, as BTX-A reduces muscle action, one cause of facial lines is, thus, reduced [4] [5] [6] [7] . For the treatment of hyperhidrosis, BTX-A activity is the result of the inhibition of the release of acetylcholine, a neurotransmitter that controls emotional, non-thermoregulatory sweating [11, 12] . However, one of the practical problems with BTX-A treatment is its variable duration of benefit against hyperhidrosis. Those patients that have a long duration of benefit (i.e., 9 months or longer)
find the treatment worthwhile, whilst those with short duration (i.e., 4 months or less) are less inclined to continue.
FACIAL INJECTION SITES FOR BTX-A
The sites of injection used to improve facial lines and, therefore, some signs of facial aging proposed [15, 16] . This has been purified by a propriety process to remove inactive proteins.
More recently, incobotulinumtoxinA has been available in Europe. usually temporary but can be of understandable concern to patients [17] . Rare side effects include headaches, paraesthesia, muscle and brow ''heaviness,'' diplopia, dry eyes, dysphagia, and dysarthria. The physician injecting BTX-A should be trained to try to avoid and correct these problems.
Resistance to BTX-A is a rare problem and the mechanism is unknown, but may involve This patient has focal deep glabellar lines and requires brow elevation. The patient was a good candidate for onabotulinumtoxin A, which was given at 2 and 4 units per site (910) resulting in a total of 32 units administered Fig. 6 Selection of toxins based on clinical features. This patient has a broad forehead, transverse lines but no brow elevation is required. The patient was a good candidate for abobotulinumtoxin A, which was given at 5 and 10 units per site, resulting in a total of 115 units administered 
COMBINATION TREATMENTS WITH BTX-A
Combination treatments are selected for appropriate patients to rejuvenate the aging face [17] . Examples of these combinations include administration of BTX-A prior to laser treatment with resurfacing lasers [17] or fractionated lasers (Figs. 8, 9 ). BTX-A is ideally delivered at least 1 week prior to laser treatment, which enables the hyperactive muscle action to be reduced; thereby, reducing the cause of facial lines. In addition, as one theory of skin rejuvenation with these laser systems is the stimulation of neocollagenesis, it is likely that less-folded skin following BTX-A leads to more uniform neocollagenesis [18] .
Other situations where combination treatments are useful is the combination of BTX-A and dermal fillers in problems such as deep vertical lower forehead lines. Here, BTX-A alone will improve, but not clear, the deep furrows that are present in some patients. The use of BTX-A plus temporary fillers can give a more prolonged effect than using the filler alone [19] . Similarly, the use of BTX-A to the upper lip area together with a filler in the upper lip can provide an adjunctive benefit to the correction of upper lip lines. Dermal fillers and BTX-A can also be combined in lower facial areas where the BTX-A is injected into areas such as the depressor angulae oris and mentalis muscles, and the filler injected into melomental folds. abobotulinumtoxinA was found to be slightly (at a 1:3 ratio) more efficient than onabotulinumtoxinA for crow's feet [21] . A recent study suggested the equivalent efficacy of 1 unit of onabotulinumtoxinA to 1 unit of incobotulinumtoxinA; however, this was only a 12 week study [22] and further comparisons would be desirable.
RECENT QUANTITATIVE STUDIES OF BTX-A FOR FACIAL LINES

DIFFERENT BTXS APPROVED IN EUROPE AND USA
A comparison of molecular characteristics and product approvals of BTXs can be seen in Table 1 , and myths and truths in Fig. 10 . 
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